By Sneha S K May 31 (Reuters) - Johnson & Johnson's prostate cancer drug Erleada used with hormone-blocking therapy six months before and after prostate surgery improved the chances of eliminating the ...

Johnson & Johnson’s PROTEUS Phase 3 trial shows apalutamide + hormone therapy before/after surgery improves outcomes in ...

Thousands of men with advanced prostate cancer could soon live longer thanks to a treatment which cuts the risk of the ...

The addition of apalutamide to androgen deprivation therapy before and after surgery improved outcomes among men with ...

With a new phase 3 win for Erleada (apalutamide), Johnson & Johnson is proposing a solution to a longstanding prostate cancer treatment gap. For patients with high-risk localized or locally advanced ...

Compared with patients receiving hormone therapy alone, patients were nine times more likely to have little to no cancer remaining in the prostate after surgery, with a 20 percent reduction in the ris ...

Researchers at Columbia University Irving Medical Center have identified a gene that drives the development of neuroendocrine ...

A whole-food plant-based diet can significantly increase weight loss for men with prostate cancer and overweight or obesity ...

Only men with a dangerous genetic variant and a family history of cancer should be offered screening, say UK advisors.

Improved radiographic progression-free survival (rPFS) regardless of disease volume or metastatic presentation achieved with ...

Researchers at Columbia University Irving Medical Center have identified a gene that drives the development of neuroendocrine ...

A breakthrough in treating an aggressive form of prostate cancer could boost survival rates, according to new research.